Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.
about
Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated CystitisPharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination TherapyThe Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Intravenous Fosfomycin for the treatment of hospitalized patients with serious infections.Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae.Fosfomycin: Pharmacological, Clinical and Future Perspectives.Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae.Molecular insights into fosfomycin resistance in Escherichia coli.Pharmacokinetics and Pharmacodynamics of Fosfomycin and its Activity against ESBL-, Plasmid-mediated AmpC- and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.Determination of the dynamically-linked indices of fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model (HFIM).Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Treatment of extended-spectrum β-lactamase-producing (ESBLs) infections: what have we learned until now?
P2860
Q26745740-A3E804C8-78F4-442E-A63E-28A8F35268B3Q37538644-7478B3DD-25AE-478F-BB17-D8FE9F87A170Q38689344-B888BDB8-EFF8-475A-8DDB-5DF466C9C4DAQ38944862-E6D49D8E-E9E4-4238-BFF4-137BC865A10AQ40049542-FF2F893E-6D35-4FD4-97F4-5855946009DBQ40166194-B1589E3E-D2E6-426B-B574-886C4B3A47E2Q40257051-89FC2565-6D2B-4316-8CD2-4FCDA0B4FBE4Q40810228-21315938-E777-488F-A09F-00FCDE5A932AQ46286730-A61E3B68-A9C0-4FC1-98BE-D984E4AD6852Q47136072-E9B66446-9F60-4DDC-B0F3-C787F18A15F0Q47561431-8BBB3E12-BDEE-4A55-AE1F-8B2301B267B5Q48197188-F7E9B9A4-89AC-4055-9413-3792C204BD17Q49196415-06DF9EC9-C52D-4920-BDC8-25B6AD3BE370Q50950504-A1EC329C-1DBC-4243-8435-07658B57DCCAQ51734361-729700B8-AE5B-470E-B9DF-293BAE52538EQ52629704-DBD3481A-2CC3-4814-BF98-17CC7BA277F7Q52695014-13ECD5F8-6DEE-4048-865A-76B4C970D53BQ58694612-07DA5151-F6F3-4B4D-B0BC-2CFE15149788
P2860
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.
@ast
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.
@en
type
label
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.
@ast
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.
@en
prefLabel
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.
@ast
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.
@en
P2093
P2860
P50
P356
P1476
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.
@en
P2093
G L Drusano
M Ballestero-Tellez
M C Conejo
M van Guilder
V Ramos-Martín
P2860
P304
P356
10.1128/AAC.00752-15
P407
P577
2015-06-29T00:00:00Z